<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339506</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002423</org_study_id>
    <nct_id>NCT02339506</nct_id>
  </id_info>
  <brief_title>Stress and the Nervous System</brief_title>
  <official_title>Stress and the Nervous System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Models of stress such as hypoglycemia have identified that stress results the next day in
      decreased baroreflex sensitivity. This project will test the hypothesis that these delayed
      changes in autonomic nervous system function are secondary to a rise in ACTH. The
      investigators will infuse cosyntropin versus placebo in a double-blind, crossover study in
      healthy adults and measure the delayed effects on the autonomic system as measured by
      cardiovagal baroreflex sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stress has complex effects on the body's physiology. Models of stress such as hypoglycemia
      have identified that stress activates the hypothalamic-pituitary-adrenal (HPA) axis and
      sympathoadrenal system acutely. Additionally, there are delayed effects of prior exposure to
      hypoglycemia. The day after being exposed to a hypoglycemic stimulus there are: 1) decreases
      in the catecholamine release to a new hypoglycemic stress; 2) decreases in the muscle
      sympathetic nerve activity (MSNA) response to either a new hypoglycemic challenge or
      transient hypotension; 3) decreases in cardiac vagal baroreflex sensitivity (BRS); and 4)
      increases in sensitivity to thermal pain and altered temporal summation (decreased tolerance
      to a repeated minimally painful stimulus). This project will test the hypothesis that these
      delayed changes in autonomic nervous system function are secondary to a rise in ACTH that
      occurs in response to stress.

      Primary Aim. Infusion of ACTH (cosyntropin) will lead the next day to decreased cardiovagal
      baroreflex sensitivity in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)</measure>
    <time_frame>Baseline, 4-hours after infusion, 24-hours after infusion</time_frame>
    <description>Cardiovagal baroreflex sensitivity will be measured with the Modified Oxford Technique before, during, and after drug infusions, to evaluate the effects of cosyntropin infusions.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pain (Quantitative Sensory Testing Using a Thermal Pain Testing Device)</measure>
    <time_frame>1 day after ACTH</time_frame>
    <description>Alterations in pain sensing will be evaluated pre and post with quantitative sensory testing using a thermal pain testing device, to evaluate the delayed effect of cosyntropin infusions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hippocampal Memory (Paired Associative Learning Task)</measure>
    <time_frame>1 day after ACTH</time_frame>
    <description>Hippocampal memory will be evaluated pre and post with a paired associative learning task</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Autonomic Nervous System</condition>
  <condition>Baroreflex</condition>
  <condition>Stress, Physiological</condition>
  <arm_group>
    <arm_group_label>Cosyntropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin</intervention_name>
    <description>Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
    <arm_group_label>Cosyntropin</arm_group_label>
    <other_name>ACTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
    <arm_group_label>Normal saline (Placebo)</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must be currently healthy, BMI 18-32 kg/m2, and not be on any medications.

        This study will recruit men and women. Due to concerns about estrogen's effects on hormone
        levels and possible contributions of menstrual symptoms on pain sensing thresholds, we will
        schedule the inpatient studies to avoid the early follicular phase in normally cycling
        women.

        Subjects must have normal laboratory values for:

          1. Complete blood count

          2. Serum creatinine, sodium, potassium, glucose, liver enzymes

          3. Urinalysis

          4. Urine pregnancy test (if female)

          5. Normal ECG

        Exclusion Criteria:

        We will exclude individuals with:

          -  Systolic blood pressure &gt; 140 or &lt; 90 mm Hg

          -  Diastolic blood pressure &gt; 90 mm Hg

          -  Creatinine clearance â‰¤ 60 mL/min, as calculated by MDRD formula

          -  Known DM, CHF, CAD, PVD, CVA, MI, asthma

          -  Known or history of Cushing's disease or adrenal insufficiency

          -  Known neurologic disease

          -  Known psychiatric disease

          -  Steroid use (oral or inhaled, local or systemic injections, within the past 6 months)

          -  Significant concomitant medical illnesses

          -  Current excessive alcohol (&gt;10oz ethanol/week)

          -  Current use of recreational drugs

          -  Current smokers

          -  Current pregnancy

          -  Chronic use of non-steroidal anti-inflammatory or narcotic medications

          -  Evidence of ischemia or heart block on screening electrocardiogram (greater than type
             I-second degree heart block, left bundle branch block, or ST-T wave changes in 2 or
             more contiguous leads)

          -  Subjects taking any prescription medications (other than oral birth control pills) or
             herbal medications will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <results_first_submitted>September 19, 2017</results_first_submitted>
  <results_first_submitted_qc>October 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gail Kurr Adler</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>stress</keyword>
  <keyword>ACTH</keyword>
  <keyword>cosyntropin</keyword>
  <keyword>baroreflex sensitivity</keyword>
  <keyword>cardiovagal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Period 1)/Washout (Period 2)/Cosyntropin (Period 3)</title>
          <description>Period 1: Subjects will receive a placebo infusion for two sessions of 2.5 hours each on day 2 of their first three day admission to our research center.
Period 2: Washout for one month Period 3: Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of their second three day admission to our research center.</description>
        </group>
        <group group_id="P2">
          <title>Cosyntropin (Period 1)/Washout (Period 2)/ Placebo (Period 3)</title>
          <description>Period 1: Subjects will receive a cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of their first three day admission to our research center.
Period 2: Washout for one month Period 3: Subjects will receive a placebo infusion for two sessions of 2.5 hours each on day 2 of their second three day admission to our research center.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Placebo or Cosyntropin)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (Period 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3 (Placebo or Cosyntropin)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)</title>
        <description>Cardiovagal baroreflex sensitivity will be measured with the Modified Oxford Technique before, during, and after drug infusions, to evaluate the effects of cosyntropin infusions.</description>
        <time_frame>Baseline, 4-hours after infusion, 24-hours after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cosyntropin</title>
            <description>Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Cosyntropin: Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline (Placebo)</title>
            <description>Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Placebo: Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)</title>
          <description>Cardiovagal baroreflex sensitivity will be measured with the Modified Oxford Technique before, during, and after drug infusions, to evaluate the effects of cosyntropin infusions.</description>
          <units>ms/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" spread="5.47"/>
                    <measurement group_id="O2" value="16.90" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-hours after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.42" spread="5.89"/>
                    <measurement group_id="O2" value="17.27" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hours after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.76" spread="5.83"/>
                    <measurement group_id="O2" value="18.90" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain (Quantitative Sensory Testing Using a Thermal Pain Testing Device)</title>
        <description>Alterations in pain sensing will be evaluated pre and post with quantitative sensory testing using a thermal pain testing device, to evaluate the delayed effect of cosyntropin infusions.</description>
        <time_frame>1 day after ACTH</time_frame>
        <posting_date>02/2018</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hippocampal Memory (Paired Associative Learning Task)</title>
        <description>Hippocampal memory will be evaluated pre and post with a paired associative learning task</description>
        <time_frame>1 day after ACTH</time_frame>
        <posting_date>02/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Cosyntropin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>Subject vomited during study, likely due to GI illness.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Subject had less blood drawn</sub_title>
                <description>Subject with normal Hct at screen (37.8), had low Hct on admission (30.8 and 31.9). Due to general wellness the study proceeded; blood draws were reduced to primary endpoints/safety and only about 40cc of blood were drawn (reduced from about 165 cc).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gail Kurr Adler</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>(617) 732-8742</phone>
      <email>gadler@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

